5-Methoxy-N,N-diisopropyltryptamine
Identification
- Generic Name
- 5-Methoxy-N,N-diisopropyltryptamine
- DrugBank Accession Number
- DB01441
- Background
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
- Weight
- Average: 274.4011
Monoisotopic: 274.204513464 - Chemical Formula
- C17H26N2O
- Synonyms
- 5-MeO-DIPT
- 5-methoxy-N,N-bis(1-methylethyl)-1H-indole-3-ethanamine
- Foxy
- Foxy methoxy
- N-(1-methylethyl)-N-{2-[5-(methyloxy)-1H-indol-3-yl]ethyl}propan-2-amine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
5-methoxy-diisopropyltryptamine, also known as 5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT, foxy methoxy, or just foxy, is a tryptamine that is used recreationally as a psychedelic. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.
- Mechanism of action
- Not Available
- Absorption
5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Tryptamines and derivatives
- Direct Parent
- Tryptamines and derivatives
- Alternative Parents
- 3-alkylindoles / Alkaloids and derivatives / Anisoles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- 3-alkylindole / Alkaloid or derivatives / Alkyl aryl ether / Amine / Anisole / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Ether show 13 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tryptamines (CHEBI:48282)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 12D06G8W8E
- CAS number
- 4021-34-5
- InChI Key
- DNBPMBJFRRVTSJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H26N2O/c1-12(2)19(13(3)4)9-8-14-11-18-17-7-6-15(20-5)10-16(14)17/h6-7,10-13,18H,8-9H2,1-5H3
- IUPAC Name
- [2-(5-methoxy-1H-indol-3-yl)ethyl]bis(propan-2-yl)amine
- SMILES
- COC1=CC2=C(NC=C2CCN(C(C)C)C(C)C)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 151182
- PubChem Substance
- 46506676
- ChemSpider
- 133247
- ChEBI
- 48282
- ChEMBL
- CHEMBL2140942
- ZINC
- ZINC000002583773
- Wikipedia
- 5-Methoxy-diisopropyltryptamine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 181 °C Not Available - Predicted Properties
Property Value Source Water Solubility 0.0673 mg/mL ALOGPS logP 4.35 ALOGPS logP 3.69 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 17.44 Chemaxon pKa (Strongest Basic) 10.68 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 28.26 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 85.24 m3·mol-1 Chemaxon Polarizability 33.06 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9949 Blood Brain Barrier + 0.9894 Caco-2 permeable + 0.5884 P-glycoprotein substrate Substrate 0.5834 P-glycoprotein inhibitor I Non-inhibitor 0.8303 P-glycoprotein inhibitor II Inhibitor 0.5672 Renal organic cation transporter Inhibitor 0.728 CYP450 2C9 substrate Non-substrate 0.8044 CYP450 2D6 substrate Substrate 0.6287 CYP450 3A4 substrate Substrate 0.7088 CYP450 1A2 substrate Inhibitor 0.9102 CYP450 2C9 inhibitor Non-inhibitor 0.8466 CYP450 2D6 inhibitor Inhibitor 0.6223 CYP450 2C19 inhibitor Non-inhibitor 0.8076 CYP450 3A4 inhibitor Non-inhibitor 0.8104 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6161 Ames test Non AMES toxic 0.6779 Carcinogenicity Non-carcinogens 0.9499 Biodegradation Not ready biodegradable 0.9964 Rat acute toxicity 2.6241 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8067 hERG inhibition (predictor II) Non-inhibitor 0.5364
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-01vo-9550000000-9ccc6b8146967b3f342e Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00b9-0590000000-0dcd2d0a3328d8b6c3e0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00dl-0090000000-75a6e64873dc12ed2a4e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-2950000000-11869d14023aa2c1ef25 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00si-1390000000-94cf6d5e37f4808beeb4 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00al-0900000000-374db0daa8a06dcc986b Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-052g-0920000000-e06aed023e954c4d568d Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 175.8091252 predictedDarkChem Lite v0.1.0 [M-H]- 169.56468 predictedDeepCCS 1.0 (2019) [M+H]+ 176.7136252 predictedDarkChem Lite v0.1.0 [M+H]+ 171.92268 predictedDeepCCS 1.0 (2019) [M+Na]+ 176.3926252 predictedDarkChem Lite v0.1.0 [M+Na]+ 178.01582 predictedDeepCCS 1.0 (2019)
Drug created at July 31, 2007 13:09 / Updated at June 12, 2020 16:51